Internal Medicine Doctors in Corozal, PR Accepting Medicare

4 Internal Medicine doctors found. Showing 1 - 4

Mr. Alwin Negron-rivera, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: Carr 891, Corozal, PR 00783 Phone: 787-859-2560

Mario Maldonado Ramirez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Calle San Manuel, Corozal, PR 00783 Phone: 787-859-0446    Fax: 787-859-3873

Mrs. Ana P Castro, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Carr 159, Urb. Monterey Calle 1 B-1, Corozal, PR 00783 Phone: 787-693-0311    Fax: 787-693-0311

Dr. Juan Luis Ortiz Matos, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Calle 1 Casa 1 Urb. Sanfeliz, Corozal, PR 00783 Phone: 787-859-0112    Fax: 787-859-6846

News Archive

Subset of TH17 cells linked to inflammation in Crohn's disease patients, find TSRI scientists

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. Patients and physicians often turn to this surgical intervention after a patient develops resistance to current treatments, such as steroids.

Dimension Therapeutics closes $30M financing to advance novel gene therapy programs

Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced the closing of a $30 million financing.

CNVs increases patients' susceptibility to severe sepsis

Genetic makeup has been identified as a key factor leading to the development of sepsis, a systemic inflammatory reaction that occurs during infection. Sepsis is considered severe when associated with organ dysfunction.

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

Newborn Possibilities program for babies at-risk for neurological injury

For every 1,000 children born in the U.S. today, two to three are at risk for developing cerebral palsy because of injuries to the brain that may have occurred prior to or during birth. There is currently no cure for cerebral palsy, but Newborn Possibilities is a first-of-its-kind program recently launched in Tucson, which may offer new options for newborns at-risk for neurological injury.

Read more Medical News

› Verified 6 days ago